Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor with the ability to
reduce myocardial hypertrophy, cardiac remodeling and cardiorenal fibrosis. The compound is
also believed to have antiarrhythmic properties as it has been shown to significantly reduce
ventricular arrhythmias in patients with implantable cardioverter defibrillators.
Patients suffering from heart failure with reduced ejection fraction show impaired heart rate
variability, knowing that in these patients such impairment is highly associated with an
increased risk of sudden cardiac death.
In its pivotal study, sacubitril/valsartan demonstrated a significant advantage over
enalapril in terms of cardiovascular mortality and rehospitalization.
Against this background, this study was designed to analyze the largely unknown
electrophysiological effects of sacubitril/valsartan on the autonomic cardiac nervous system
by determining heart rate variability.